The Safety Pharmacology Society (SPS) conducted an industry survey in 2015 to identify industry practices as they relate to central, peripheral and autonomic nervous system ("CNS") drug safety testing. One hundred fifty-eight (158) participants from Asia (16%), Europe (20%) and North America (56%) responded to the survey. 52% of participants were from pharmaceutical companies (>1,000 employees). Oncology (67%) and neurology/psychiatry (66%) were the most frequent target indications pursued by companies followed by inflammation (48%), cardiovascular (43%), metabolic (39%), infectious (37%), orphan (32%) and respiratory (29%) diseases. Seizures (67% of participants), gait abnormalities (67%), tremors (65%), emesis (56%), sedation (52%) and salivation (47%) were the most commonly encountered CNS issues in pre-clinical drug development while headache (65%), emesis/nausea (60%), fatigue (51%) and dizziness (49%) were the most frequent issues encountered in Phase I clinical trials. 54% of respondents reported that a standard battery of tests applied to screen drug candidates was the approach most commonly used to address nonclinical CNS safety testing. A minority (14% of all participants) reported using electroencephalography (EEG) screening prior to animal inclusion on toxicology studies. The most frequent group size was n=8 for functional observation battery (FOB), polysomnography and seizure liability studies. FOB evaluations were conducted in a dedicated room (78%) by blinded personnel (66%) with control for circadian cycle (55%) effects (e.g., dosing at a standardized time; balancing time of day across treatment groups). The rat was reported as the most common species used for seizure liability, nerve conduction and drug-abuse liability testing.
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Introduction
With 41 new FDA approved drugs, 2014 was a greater than average year for the pharmaceutical and biotechnology industry (Anon. 2015) . This article focuses on CNS drug safety testing, the dynamics between development and Safety Pharmacology methods and strategic approaches that have been taken to garner marketing authorization of a new molecular entity (NME) under New Drug Applications (NDAs) or as new therapeutic biologic under a Biologics License Application (BLA). The aging population has benefited from a moderate but progressive increase in drug development efforts for neurological indications (Melnikova, 2010) and the CNS drug market is forecast to grow to $81.8 billion in 2015 (BCC Research, 2010) .
Despite this growth to become the 2 nd most important therapeutic indication in drug development, CNS indications present a challenge since CNS drugs are reported to take longer to get to market and their attrition rate is greater than other therapeutic indications (Palmer & Alavijeh, 2012) .
Market size and level of unmet need determine the clinical importance of drug development within a given therapeutic area which, in turn, reflects upon non-clinical professional disciplines such as Safety Pharmacology (SP). In general terms, although drug approval rates appear to have increased, drug attrition remains a major hurdle in pharmaceutical development (Moreno & Pearson, 2013; Hay et al., 2014; Cook et al., 2014; Waring et al., 2015) . A tendency towards an increased failure rate in Phase 3 clinical trials due to safety issues has been reported over a 5 year period (Arrowsmith & Miller, 2013) . Oncology remains the largest therapeutic market, with sales exceeding US$100 billion in 2014 after a double digit increase in the previous year (Mullard, 2015) . In oncology, neurological adverse effects remain one of the most frequent cause of drug failure (Valentin & Hammond, 2008; Cook et al., 2014) , second only to cardiac adverse effects.
Although non-clinical cardiac SP assessment models and testing strategies have been extensively evaluated (Porsolt et al., 2002; Pugsley et al., 2009; Valentin et al., 2010; Authier et al., 2010; Vargas et al., 2015; Klein & Redfern, 2015) , only limited information is available with respect to CNS adverse effect testing strategy and practices. At the more granular level, there are comprehensive reviews of non-clinical CNS models for seizure (Bassett et al., 2014; Easter et al., 2009; Metea et al., 2015; Fonck et al., 2015) and drug abuse liabilities (Kallman, 2015; Moser et al., 2010; Porsolt et al., 2002 " O"Connor et al., 2011 , with consideration of specific screening models for seizure (Authier et al., 2009; Koseki et al., 2014) , sleep (Authier et al., 2014) and peripheral nerve function (Zotova & Arezzo, 2013 ). However, current industry A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Authier et al 2015 JPTM 6/2/2016 practices and trends as they relate to the use of these models in drug development are not well characterized (Lindgren et al., 2008) .
In view of these considerations, a survey was undertaken by the SPS to evaluate current (defined as during the last 5 years) industry practices for CNS drug SP testing, and the present paper reports the findings.
Results
All results are presented as the percentage of total response rate per question, as percentage of total number of scientists that responded to each question or number of responding scientists.
Study Survey Demographics
Scientists (n=158) from various fields of expertise (Fig. 1A) and location (Fig. 1B) participated in the survey which represented a response rate of 35.3% (158 out of 447 invited). A predominance of participants from North America was inevitable owing to the greater proportion of scientists from this geographical region in the population solicited to take this survey.
Participants were distributed between diverse organization types ( Fig. 1C) and sizes ( Fig. 1D) , with more than half from larger companies (>1000 employees). As a result, it is expected that larger companies have contributed multiple respondents from the same organization.
Consequently, the results from the survey predominantly reflect practices and perceptions of individuals working in larger institutions. The survey identified some interesting peripheral facts, such as the primary therapeutic areas that were targeted by the companies employing survey participants. Oncology (67%) and neurology/psychiatry (66%) followed by inflammation (48%), cardiovascular (43%), metabolic (38%), infectious (37%), orphan (32%) and respiratory (29%) diseases were the most frequent target therapeutic areas reported (Fig. 1E ).
Drug SP Testing for the CNS: Survey results
Over the last 5 years seizures (67% of participants), gait abnormalities (67%), tremors (65%), emesis (56%), sedation (52%) and salivation (47%) were the most commonly encountered CNS issues in pre-clinical drug development (Figure 2 ), whereas headache (65%), emesis/nausea (60%), fatigue (51%) and dizziness (49%) were the most frequent issues encountered in Phase I clinical trials (Figure 3) . A minority (14% of all participants) reported using pre-study EEG screening of individual animals prior to inclusion in general toxicology studies. A standard battery of tests applied to screen all drug candidates was the approach that best described the strategy used by the company for 54% of participants, whereas 37% selected issue resolution for an in-depth understanding of these assays (Gauvin et al., 1997; Himmel, 2008; Redfern et al., 2005 of participants and on selected parameters by 29%. The remainder, 27% did not undertake statistical analysis on FOB data (this probably refers to the incidence data).
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Seizure Liability Testing
A majority (55%) of respondents to the survey had conducted or interpreted non-clinical seizure studies within the last 5 years. A minority (19%) of participants routinely conducted seizure studies during the early drug-screening phase of development. Conversely, 76% of participants conducted seizure studies based on results from other studies, and only 10% would terminate development of a compound when seizure liability is present. The therapeutic indication is likely to affect the decision taken in presence of a seizure liability but this was not evaluated in the current survey. A vehicle control (87%) and a positive control (53%) group were included by most participants in seizure liability studies (Table 5 ) but toxicokinetic (39%), cerebrospinal fluid (17%) and brain tissue (28%) samples were taken only by a minority of participants. The most frequent group size for seizure liability studies was n=8 ( Figure 5 ). Fifteen percent of participants reported conducting all seizure liability assessments under GLP, 43% reported using GLP and non-GLP studies and 43% reported using non-GLP seizure liability studies only (Table 3 ). This presumably reflects that most seizure liability studies are conducted early in development. As a general principle, one would expect GLP work to be done later in development when candidates with easily identifiable liabilities have been excluded from further development. It appears that there are methods that can be used to identify drug candidates with seizure liabilities early in development before the need to conduct GLP arises (Löscher et al., 1991; Pollack & Shen, 1985) . The rat was the most frequently used species with which to test the seizure potential (91%), followed by the mouse (47%) ( Table 6 ). Similarly, rats (87%), dogs (45%), mice (39%) and monkeys (31%) were the most frequently used species when EEG recording was undertaken (Fig. 6 ). Implanted EEG electrodes (59%) and video monitoring (57%) were the most common methodology used followed by surface/cutaneous EEG (44%) ( Table 7) . Manual seizure detection (62%) was used more commonly than automated detection (25%). When implanted EEG electrodes were used, the anatomical plane in which the electrodes were implanted was approximately uniformly distributed between subcutaneous (35%), cortical bone (23%), surface of the dura mater (35%) and brain parenchyma (19%).
When questioned on interpretation of seizure liability study data, 58% considered that historical data may be used to dismiss an animal with seizure after drug dosing, especially in dogs, and 52% considered the Beagle dog as an appropriate species for seizure liability studies. The presence of clinical signs compatible with seizures needs to be interpreted in relation to drug administration and historical data may be considered to determine if the condition represents a background observation in the model irrespective of treatment or a consequence of dosing.
Some participants suggested that pre-study EEG screening was required for Beagle dogs to Authier et al 2015 JPTM 6/2/2016 ensure suitability for the studies. A majority of participants (73%) considered that a safety margin of 10X to NOAEL for seizures was required while other participants considered 30X
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preferable, but a safety margin lower than 10X was also reported as acceptable in certain circumstances.
Juvenile CNS Testing
A majority (73%) of respondents had conducted or interpreted non-clinical juvenile CNS testing in the last 5 years. Rats (79%) and mice (32%) were the most common species used for juvenile CNS SP testing followed by non-human primates (24%) and dogs (15%) (Figure 7 ).
This presumably reflects the stage in drug discovery and development in which the testing was undertaken (late stage, and lead candidate, reflected by use of larger mammals or primates). As expected, FOB was the most frequent (91%) juvenile CNS safety assay followed by memory tests (43%), learning tests (40%) and mazes (34%). The Morris water maze was the type most frequently (70%) reported.
Polysomnography (Sleep) Studies
Only 21% of participants had conducted or interpreted polysomnography studies in the previous 5 years. A dose escalation design had been used by 42%, a cross over design by 39%, a repeat dose design had been used by 26%, and 42% of participants reported reusing animals in sleep studies. The dose group size used in these studies varied from 3-12, with n=8 reported to be used most frequently. Smaller group sizes were reported for larger species (i.e., non-human primates). EEG (67%), video monitoring (53%), EMG (43%) and body temperature (43%) were the most frequently used parameters (Table 8) . Sleep scoring was undertaken using automated (37%), manual (30%) or both (30%) methodologies.
Peripheral Nerve Conduction Studies
A minority of participants (28%) had conducted or interpreted peripheral nerve conduction studies in the last 5 years. Peripheral nerve conduction was added to a toxicology study by 54% while 49% conducted standalone studies. A repeat dose design (51%) was most frequent but a single dose (19%) or dose escalation (8%) designs were also reported for peripheral nerve function studies. Group size ranged from 6-20 and was reported to typically match the group size for the repeat dose toxicology study. Participants reported conducting peripheral nerve conduction studies under GLP (24%), non-GLP (38%) or both (38%) ( Table 3 ). The rat was the most frequently reported species (72%) ( Table 9 ) used for peripheral nerve conduction assessments. Nerve conduction velocity (68%) and histopathology (62%) were the most frequently selected parameters when conducting peripheral nerve toxicity tests (Table 10) .
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Drug Abuse Potential Studies
Half (51%) of the participants had conducted or interpreted drug abuse potential studies in the previous 5 years. A typical group size of n=10 was reported for rats and 3-5 for non-rodents.
When conducting standalone studies, self-administration (73%), drug withdrawal (47%) and drug discrimination (40%) were the most frequent study types reported by participants. Rat was the most common species (81%) used followed by non-human primate (38%), mouse (19%) and rabbit (6%).
In Vitro Models of CNS Adverse Effects and Other Techniques
In vitro models of CNS adverse effects had been used by a relatively limited proportion of participants. Hippocampal brain slice electrophysiology for seizure liability (30%), neuronal cell lines (27%), in vitro blood brain barrier models (20%), neuronal/glial co-culture (17%) and hippocampal brain slice electrophysiology for long-term potentiation (17%) were the most frequently reported models (Table 11 ). The larval zebrafish seizure assay (15%), stem cell derived neurons (14%) and brain slice electrophysiology studies using other brain regions (13%)
were less commonly used (Table 11) .
Discussion
The current survey aimed to identify current strategies for non-clinical drug SP testing as they relate to CNS adverse effects. Participants were distributed across four continents and originated from diverse company types and sizes. Oncology and neurology were the most frequent indications for which new therapies were developed. The increasing size of the aging population is projected to double the incidence of CNS diseases by 2050 (Wright et al., 2010; Alzheimer's Association, 2015) . Concurrently, mortalities from heart diseases, stroke and prostate cancer are expected to decline (Nowbar et al., 2014; Torre et al., 2015) . In view of this, CNS adverse effect liability and testing for liability are likely to become more important since drugs for CNS indications (including psychiatric and neurological indications, as well as drugs targeting brain tumors and metastases) represent the broad class with the greatest risk of CNS adverse effect liability, because by nature these agents are CNS active and/or CNS penetrant.
Seizure, gait abnormalities and tremors were the most frequent CNS issues detected in nonclinical drug SP testing in the last 5 years. The incidence of seizures in the elderly population is estimated to be 10-fold higher than in adults (Elberly et al. 2010 , Hauser et al., 1993 .
Susceptibility to drug induced seizures is generally increased in a population with a history of A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Authier et al 2015 JPTM 6/2/2016 seizure. Concomitantly, a majority of individuals over the age of 60 take more than three prescription drugs (Gu et al., 2010 ) supporting a positive correlation between age and the use of polypharmacy. The increasing incidence of seizures with age combined with the frequent use of prescription drugs in an older population places seizure liability testing in a critical position with respect to the risk for adverse drug reaction (ADR). Potentially fatal ADRs such as arrhythmias and seizure mandate a higher level of risk assessment. Drug induced seizures are important medical events with significant impact to patients and are also considered a serious adverse event owing to the potential for status epilepticus, a life-threatening condition that manifests as continuous or rapidly repeating seizures (Gastaut, 1970; Lowenstein et al., 1998) The FOB/Irwin Test can capture a wide range of drug-induced CNS effects (Redfern et al., 2005) and may be adapted to most laboratory animal species including rats (Himmel, 2008) , mice (Irwin, 1968) , minipigs (Giarola et al., 2008) , dogs (Moscardo et al., 2009 ) and non-human primates (Gauvin & Baird, 2008; Moscardo et al., 2010; Authier et al., 2012) . This survey identified the rat as the most frequently used species for FOB studies followed by mice, nonhuman primates and dogs in approximately equivalent proportions. The abundant historical data in rats and the predominant use of rats as the rodent species for regulatory toxicology studies justifies its selection by default. Species selection is subjected to a plethora of other factors such as pharmacokinetics, metabolism and receptor affinity as well as genetic and phenotypic homology just to name a few. Most participants reported conducting FOB evaluations as standalone studies with three dose levels. Half of the participants (54%) from the current survey reported experience with a design in which a FOB was added to toxicology studies. In a previous industry survey conducted in 2012 by the SPS, 34% of participants had experience with inclusion of FOB in toxicology studies (Authier et al., 2013) , possibly indicating increasing experience with the study designs and/or increasing development of biotherapeutic agents over the last three years. When conducted by experienced groups, FOB/Irwin Test assessments were shown to be robust to identify CNS drug effects with known CNS-active agents (Porsolt et al., 2002; Moscardo et al., 2007; Redfern et al., 2005; Ewart et al., 2013) , justifying the addition of CNS endpoints in toxicology studies, useful in a 3R"s context (Redfern et al., 2013; Redfern, 2015) . A wide range of group sizes was reported (i.e. n=3 to 30), but a majority of respondents (Moscardo et al., 2007; Markgraf et al., 2010) to identify drug effects in FOB studies. Results from the current survey confirm that a majority of participants undertake statistical analysis (combined 74%), at least for some parameters. For example, Redfern et al. (2005) and Ewart et al (2013) performed statistical analysis of their FOB continuous data and counts, but used a rule-based approach for their incidence data. In simple terms, incidence of an observed parameter was considered noteworthy if it occurred in 50% of the treatment group, the reason being that statistical significance of P<0.05 for group sizes of 6 (using Fisher"s Exact Test) requires 5/6 rats to exhibit the effect. Setting a lower threshold than this (ie, 3/6) is arguably prudent when in the business of hazard detection. Statistical analysis is more appropriate when using a larger group size and when ranking the severity of the observed parameters, but even so, when Markgraf et al. (2010) Pharmacological effects identified during FOB may differ between adult and juvenile animals (Himmel, 2008) , justifying careful designs supported by regulatory guidance documents (EMEA, 2008; FDA, 2006) to investigate possible neurotoxicity in a younger population when applicable. Authier et al 2015 JPTM 6/2/2016 A wide range of approved drugs are associated with drug induced sleep disturbances such as insomnia, including beta-blockers (Chang et al., 2013; Moser, 1979) , corticosteroids (Ciriaco et al., 2013) , selective serotonin-reuptake inhibitors (SSRI) (Asnis, et al., 1999) or acetylcholinesterase inhibitors (Cooke et al., 2006) . Polysomnography is a well-established technique for sleep disturbance assessment and is well established in laboratory animal species commonly used for non-clinical drug SP testing including rodents (Gotter et al., 2013) , dogs and non-human primates (Authier et al., 2014) .
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The current survey highlights a high diversity in study designs and methodologies reflecting differences in therapeutic target and stage in the pipeline of drug development. For example, the impact of drug-induced sleep disturbance on drug success depends on the indication since more severe conditions (e.g., oncology) are considered less sensitivity to a potential change in sleep architecture given the severity of the disease and the shorter treatment period compared to other chronic conditions typically requiring lifelong therapies (e.g., diabetes, heart diseases, allergies, neurodegenerative diseases). Moreover, the impact of any adverse effect is entirely dependent on the therapeutic indication; for example, if a drug can treat cancer more effectively than any other, but has some adverse effects on sleep, the drug will be used, whereas if the indication is cough, it is not likely . More exhaustive non-clinical polysomnography studies are more likely to be undertaken for the non-life threatening indications for which drug induced sleep disturbances may have a more clinically relevant impact on the patient population. The tolerance for drug-induced undesired effects is recognized to increase with the severity of the disease that is treated .
Peripheral neuropathies are a common limiting factor with oncology chemotherapeutic drugs (Quasthoff & Hartung, 2002; Wolf et al., 2008; Argyriou et al., 2007) . Although the characterization of underlying mechanisms (Berg & Parsons et al., 2015; Bobylev et al., 2015; Li et al., 2015) is progressing and pharmacogenomic strategies are emerging (Gambarotta et al., 2014) , non-clinical electrophysiology models and behavioral assessments (mechanical allodynia and hyperalgesia) remain a cornerstone to identify drug-induced peripheral neuropathies. The rat is the most frequently used species for peripheral nerve function assessments. Rats were successfully used to identify peripheral neuropathy induced by chemotherapeutic drugs such as carboplatin (Cavaletti et al., 1998 ), cisplatin (Bianchi et al., 2006 ), paclitaxel (Cavaletti et al., 1997 and vincristine (Alimoradi et al., 2012) . Like any non-clinical model, the translational potential of peripheral nerve conduction tests remains imperfect. This is illustrated by Authier et al 2015 JPTM 6/2/2016 thalidomide which is associated with peripheral neuropathy in patients (Kocer et al., 2009 ) but failed to alter sensory nerve conduction velocity in a chronic toxicology study in Beagle dogs (Teo et al., 2000) . Although it is often omitted, the reporting of both nerve conduction and histopathology findings should include the location of the points of assessments along a distalto-proximal gradient. The absence of deficits measured at a relatively proximal site may yield a false negative finding in the presence of a "length-dependent distal axonopathy (Arezzo, J.C., et al., 2011) ." This is especially true for sensory neuropathies manifested in the elongated caudal nerve of the rat (Schaumburg et al., 2010) .
The current survey suggests that drug abuse liability was amongst the most frequent CNS follow-up SP studies conducted with 51% of the participants that had conducted or interpreted drug abuse potential studies in the last 5 years. As previously reported, drug abuse liability studies are conducted GLP or non-GLP (Moser et al., 2011) . Robust scientific literature exists to support the use of rats for regulatory drug abuse liability studies (O"Connor et al., 2011; Hudzik et al., 2013; Teuns et al., 2014) and this was echoed in the current survey in which a large majority (81%) of participants reported using this species. Amongst survey participants with experience in drug abuse liability testing, the three core pieces of behavioral data required in the overall abuse liability analysis (Ator & Griffiths, 2003) were the most frequently used (i.e., selfadministration (73%), drug withdrawal (47%) and drug discrimination (40%)). Participants reported a higher frequency of regulatory feedback on drug abuse liability studies when compared to other CNS drug safety testing areas. Drug abuse liability studies are expected as part of the End of Phase 2 package for CNS-active drugs and therefore the high frequency of regulatory feedback is not unexpected. Furthermore, these well-defined studies are reported in the literature (Gauvin et al., 2015) and regulatory guidelines (EMEA, 2006; FDA, 2010) , which can be used to support the study design rationale.
Conclusion
In conclusion, this industry survey conducted by the Safety Pharmacology Society (SPS) provides a snapshot of the current non-clinical CNS drug SP testing landscape. It confirms a number of well-accepted paradigms but also reveals study design trends for common follow-up models in CNS SP. Functional endpoints in CNS SP should exhibit high sensitivity and high translational value. Future non-clinical CNS industry surveys will reveal whether improvements have been made in this regard. While this industry survey covered frequently used pre-clinical CNS safety testing models, the field is rapidly progressing with emerging considerations and assays such as neuropsychiatric liability, negative affective bias models, intracranial self- Cavaletti, G., Cavalletti, E., Montaguti, P., Oggioni, N., De Negri, O., & Tredici, G. (1997) . Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology, 18, 137-145.
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Cavaletti, G., Fabbrica, D., Minoia, C., Frattola, L., & Tredici, G. (1998) . Carboplatin toxic effects on the peripheral nervous system of the rat. Annals of Oncology, 9, 443-447. Although emesis/nausea and fatigue are not typically considered CNS issues from a clinical adverse event terminology perspective, they have been included in this assessment due to the notion that the event reporting requires the element of perception that is under CNS control. Body temperature 43% 13 * Participants selected all that applied. Which parameters were evaluated in peripheral nerve safety testing studies (Select all that apply)?*
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